Henrik Stender Henrik Stender joined the board of ViroGates in august 2020.Owner of Stender Diagnostics. Education: M.Sc. in Chemical Engineering and Ph.D. in Immunology from Technical University of Denmark; B. Comm. in Business Informatics and Economics, Copenhagen Business School. Competencies: 30 years of international experience with all aspects of development of innovative in vitro diagnostic (IVD) medical devices improving patient care; strong track-record of regulatory approvals, incl. +20 U.S. FDA clearances, covering infectious diseases, immune-monitoring and cancer; broad range of scientific management positions; inventor; founder; board member. Directorships: \u2022 Visiopharm A\/S (BM) Shareholdings: Shares: 0, Warrants (vested): 0 (30 September 2020) Henrik is independent of the issuer, major shareholders and senior management.Lars Krogsgaard Lars Krogsgaard joined the board of ViroGates in April 2016. Professional board member and investor Education: B.Sc. in Economics, Copenhagen Business School; MBA in Finance and International Business, Stern School of Business, New York. Competencies: Track-record as active investor, owner and board member in more than 25 Nordic companies incl. other growth companies; strategic development; business development; risk management; financing, M&A. Directorships: \u2022 Daintel ApS (BM) \u2022 DCR Solutions A\/S (BM) \u2022 Forward Capital A\/S (BM, M) \u2022 4AM ApS (M) \u2022 Samplix A\/S (MB) \u2022 6AM ApS (M) Shareholdings: Shares: 325,965, Warrants (vested): 0 (30 September 2020) Lars is not an independent director.J\u00f8rgen Thorball J\u00f8rgen Thorball founded ViroGates with Jesper Eugen-Olsen and Peter Benson in 2001. Managing Partner at XOventure GmbH Education: MD, University of Copenhagen Competencies: Life science entrepreneur and founder of several companies, many of them based on his own medical inventions; management and board positions in listed blue-chip pharma companies; financing; M&A. Directorships: \u2022 3Brain AG (C) \u2022 BioMe AS (BM) \u2022 Retipharma A\/S (BM) \u2022 Rigi Care (M) Shareholdings: Shares: 10,204, Warrants (vested): 20,139 (30 September 2020) J\u00f8rgen is independent of the issuer, major shareholders and senior management. Lars Kongsbak Lars Kongsbak joined ViroGates in February 2015 as Chairman of the Board. President and CEO of Samplix ApS Education: M.Sc. in Biology, Copenhagen University; Ph.D. in molecular biology from the Technical University of Denmark (DTU) Competencies: Former President & CEO of listed biopharmaceutical company; strategic business development; M&A; financing, broad-based leadership experience; senior scientist positions at blue-chip companies. Directorships: \u2022 BlueBee Holding BV (BM) Shareholdings: Shares: 6,968, Warrants (vested): 37,070 (30 September 2020) Lars is independent of the issuer, major shareholders and senior management.